Aggressive chemo schedule put to the test in brain cancer trial

NCT ID NCT03663725

Ongoing Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether giving the chemotherapy drug temozolomide earlier and for a longer time can help adults with glioblastoma live longer. About 486 participants will receive either the standard treatment or an intensified version that starts chemo within two weeks of surgery and continues until the cancer progresses or side effects become too severe. The study aims to see if this more aggressive approach improves overall survival compared to the usual six-cycle regimen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: temozolomide (chemotherapy)
What this could lead to: If successful, this could show that starting chemotherapy earlier and continuing it longer helps people with glioblastoma live longer.
What could go wrong: This is a phase 3 trial, but glioblastoma is very aggressive and hard to treat. The intensified regimen may cause more side effects without improving survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

APHP La Pitié Salpêtrière

Paris, 75013, France
CH René Dubos

Pontoise, 95300, France
CHRU Nancy

Nancy, 54000, France
CHRU Tours

Tours, 37044, France
CHU Grenoble Alpes

Grenoble, 38043, France
CHU La Timone

Marseille, 13385, France
CHU de Limoges

Limoges, 87042, France
CHU de Nice - Hôpital de Cimiez

Nice, 06000, France
Centre François Baclesse

Caen, 14076, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Hospitalier d'Amiens

Amiens, 80054, France
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Léon Bérard

Lyon, 69673, France
Centre Paul Strauss

Strasbourg, 67065, France
Hôpitaux Civils de Colmar

Colmar, 68024, France
ICM Val d'Aurelle

Montpellier, 34298, France
Institut Cancérologie Loire

Saint-Priest-en-Jarez, 42270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.